Tempus and NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will support NYU Langone ...
"The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage ...
RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...
Tempus AI (NASDAQ: TEM), a healthcare technology company, posted impressive Q1 results with revenue reaching $255.7 million, up 75.4% year-over-year. Adjusted EBITDA improved significantly to $-16.2 ...
Chicago artificial intelligence giant Tempus AI is showing it's operating in the black after 10 years and growing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results